Evidence Table B3: DISCRETE outcomes for class KERATOLYTIC (TOPICAL).

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
	B.01.01			**Azelaic acid**	**Placebo**	
77 ↑ Parallel N=40		**Local side effects**		Present 2 Absent 18	Present 1 Absent 19	
	B.01.01			**Azelaic acid**	**Vehicle**	
187 ↑ Parallel Mod N=92		**Burning**	Mid (12)	Present 4 Absent 39	Present 1 Absent 48	
		Erythema	Mid (12)	Present 2 Absent 41	Present 1 Absent 48	
		Itching	Mid (12)	Present 2 Absent 41	Present 0 Absent 49	
		Overall change/physician	Mid (12)	Excellent or good 28 Other 15	Excellent or good 18 Other 31	**0.05**
		Scaling	Mid (12)	Present 1 Absent 42	Present 2 Absent 47	
	B.03.01			**Salicylic acid**	**Placebo**	
294 ↓ Parallel Mild/mod N=30		**Acne change**	Short (5)	Greater than match 10 Equal 8 Worse than match 0	Greater than match 0 Equal 8 Worse than match 10	
		Oiliness change	Short (5)	Greater than match 11 Equal 7 Worse than match 0	Greater than match 0 Equal 7 Worse than match 11	
		Local reactions	Mid (9.5)	Skin burning 10 Eyes burning 1	Skin burning 0 Eyes burning 0	
		Oiliness change	Mid (9.5)	Greater with match 5 Equal 6 Worse than match 6	Greater with match 0 Equal 6	
		Acne change	Mid (12)	Greater than match 7 Equal 4 Worse than match 0	Greater than match 0 Equal 4 Worse than match 7	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
	B.05.02			**Sulfurated lime**	**Vehicle**	
101 Parallel Mod N=59		**Severity change**	Mid (10)	Excellent 9 Moderate 10 Slight 1 No change 6	Excellent 2 Moderate 5 Slight 2 No change 4	**0.015**
				Worse 4 Dropouts 0	Worse 9 Dropouts 7	
	B.06.01			**Komed® (sulfur + salicylic acid + resorcinol)**	**Placebo**	
191 ↑ Parallel split face Mild/mod/sev N=51		**Overall change/physician**		Komed® - proprietary 6 Komed® better than proprietary 7 Komed® worse than proprietary 4 Komed® - placebo 13 Komed® better than proprietary 21	Komed® - proprietary 0 Komed® better than proprietary 0 Komed® worse than proprietary 0 Komed® -placebo 13 Komed® better than proprietary 21	
				Komed® worse proprietary 0	Komed® worse proprietary 0	
	B.06.02			**Komed® (sulfur + salicylic acid + resorcinol)**	**Proprietary formula (sulfur + salicylic acid + re**	
191 ↑ Parallel split face Mild/mod/sev N=51		**Overall change/physician**		Komed® - proprietary 6 Komed® better than proprietary 7 Komed® worse than proprietary 4 Komed® - placebo 13 Komed® better than proprietary 21	Komed® - proprietary 6 Komed® better than proprietary 7 Komed® worse than proprietary 4 Komed® -placebo 0 Komed® better than proprietary 0	
				Komed® worse proprietary 0	Komed® worse proprietary 0	
	B.07.01			**Aluminum chloride**	**Vehicle**	
165 ↑ Parallel split face Mild/mod N=25		**Overall change**	Mid (8)	Improved 10 No difference 3 Worse 10	Improved 3 No difference 4 Worse 16	**NS**
	B.07.02			**Aluminum chlorhydroxide + sulfur**	**Vehicle**	
228 Parallel N=776		**Overall change/physician**	Short (5)	Improved 142 Not improved 59	Improved 76 Not improved 75	**0.001**

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
	B.07.04			**Gluconolactone**	**Vehicle**	
176 ↓ Parallel Mod/sev N=150		**Local effects**		Dryness, scaling, burning, stinging, redness 11 None 34	Dryness, scaling, burning, stinging, redness 5 None 41	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.